Mr. Arguedas et al., Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis, ALIM PHARM, 15(5), 2001, pp. 631-638
Objectives: Clinical trials are currently underway evaluating the efficacy
of COX-2 inhibitors in decreasing the incidence of adenomas and colorectal
carcinoma in 'average' risk individuals.
Aim: To use decision analysis to compare the cost-effectiveness of celecoxi
b to surveillance colonoscopy in 'average' risk patients who had undergone
prior adenoma resection.
Methods: A model of the natural history of adenomas after endoscopic polype
ctomy was constructed using probabilities from the literature. Cost estimat
es were obtained from available Medicare reimbursement rates and supplement
ed by the literature. Three strategies were evaluated: (i) no surveillance;
(ii) colonoscopic surveillance; and (iii) celecoxib chemoprevention. We co
mpared total costs and performed cost-effectiveness analysis between these
strategies. The outcome measures were years of life saved and 'high-grade'
adenoma prevented. Sensitivity analyses were performed on selected variable
s.
Results: Our base-case analysis assumed a 50% risk reduction in the inciden
ce of adenomas among patients using cerecoxib. No surveillance was associat
ed with a cost of $1014 per patient, and colonoscopic surveillance with a c
ost of $1572 per patient, whereas celecoxib use was associated with a total
cost of $11 503. Ten years after the index colonoscopy, 15% of patients in
the no surveillance strategy developed 'high-grade' lesions compared to 13
% of patients in the colonoscopic surveillance group and 6% in the celecoxi
b group. There was a small gain in years of life saved (0.006) favouring ce
lecoxib over colonoscopic surveillance. The incremental cost-effectiveness
ratio of celecoxib vs. colonoscopy was $141 871 per 'high-grade' adenoma pr
evented and $1 715 199 per year of life saved. The most important variables
in determining the cost-effectiveness of celecoxib were its cost and its e
fficacy.
Conclusion: Chemoprevention with COX-2 inhibitors in 'average-risk' postpol
ypectomy patients is a more expensive strategy compared to colonoscopic sur
veillance.